Elliott Statement on ARYZTA
Elliott Advisors (UK) Limited (“Elliott” or “we”) notes the press speculation regarding a potential offer for ARYZTA AG (the “Company”) and issues the following clarification.
Elliott confirms that on Wednesday November 18th 2020 it made a proposal to the Board of Directors of the Company to potentially acquire all of the outstanding shares of ARYZTA AG for an indicative price of CHF 0.80 per share. This followed several months of work conducted with the support of the Company and its Board of Directors, both before and after the Extraordinary General Meeting on September 16th 2020. We also note press speculation regarding the financing for such an acquisition and the refinancing of the Company. We confirm that the financing of the potential offer is available and that refinancing arrangements for the Company’s existing debt are at a very advanced stage. We require the Board of Directors’ recommendation of our potential offer and the Company’s support to finalise our refinancing arrangements.
The public tender offer would be subject to customary offer conditions to be specified by Elliott. The information contained in this statement is neither an offer to purchase shares in ARYZTA AG nor a solicitation of an offer to sell ARYZTA AG shares or any other securities of ARYZTA AG nor does it constitute a public tender offer with respect to any ARYZTA AG shares or any other ARYZTA AG securities.
About Elliott
Elliott Management Corporation manages approximately $41 billion of assets. Its flagship fund, Elliott Associates, L.P., was founded in 1977, making it one of the oldest funds of its kind under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Management Corporation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201122005093/en/
Contact information
London
Sarah Rajani CFA
Elliott Advisors (UK) Limited
T: +44 (0)20 3009 1475
srajani@elliottadvisors.co.uk
Switzerland
Martin Meier-Pfister
IRF
T: +41 43 244 81 40
M: +41 79 200 85 00
meier-pfister@irf-reputation.ch
Ireland
Jack Hickey
Powerscourt
T: +353 (0)1 536 0683
M: +353 (0)83 448 8339
jack.hickey@powerscourt-group.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SciencePower Collaborates to Advance Research on Postbiotics in Breast Cancer Biology9.12.2025 14:00:00 EET | Press release
SciencePower, a next-generation postbiotic platform company, today announced that it has entered into a license agreement with Mayo Clinic. The agreement enables collaborative research led by Mayo Clinic investigators to explore the potential of SciencePower’s proprietary postbiotic compositions in breast cancer biology. The collaboration will focus on understanding how specific microbiome-derived compositions influence immune and cellular pathways relevant to breast cancer. Early preclinical findings are currently planned to be presented at the San Antonio Breast Cancer Symposium (SABCS) in December 2025. “This milestone marks an important step in validating our technology through rigorous scientific collaboration,” said Robin Albin, SciencePower Co-Founder, Marketing & Communications. “We are honored to work with Mayo Clinic researchers to deepen the understanding of postbiotics and their potential role in advancing human health.” Mayo Clinic has a financial interest in SciencePower
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET9.12.2025 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company’s commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders’ perspectives on the current treatment landscape and the significant unmet need in treating both TRD and PTSD. The company’s collaboration partners will discuss patient care pathways, provider economics for multi-hour treatments, and the development of treatment models in TRD. Compass Pathways’ management team will review commercial readiness activities and the emerging profile of COMP360 in TRD, as well as highlight the unmet need in post-traumatic stress disorder (PTSD) and provide details of the planned late-stage program for COMP360 in
Brands Poised for Growth: NIQ Identifies the Strategies Behind 2025’s Top Performing Innovations9.12.2025 13:00:00 EET | Press release
NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today released its 4th Annual Innovation Vitality Report, revealing the strategies that are helping brands achieve multi-year growth from their innovation pipelines. Drawing on data from over 70,000 manufacturers across 130 categories, the report highlights the practices that double a company’s likelihood of expanding overall sales through top performing innovation. As retailers accelerate shelf refresh cycles and private label competition intensifies, brands are under increasing pressure to design innovations with staying power. NIQ’s findings show that top performing innovators consistently follow a repeatable formula, rooted in strong consumer-led ideas, early performance signals, and cross functional alignment, to build products that deliver long-term, incremental growth across global markets. Key Findings from the 2025 Innovation Vitality Report Winning Innovation Starts Before Launch Brands that invest in true innov
Klarna Now Available on Apple Pay to Customers in France and Italy9.12.2025 12:49:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, has made its flexible payment products available when checking out on Apple Pay in France and Italy. Millions of eligible shoppers can now choose Klarna at checkout online and in-app using their iPhone and iPad, or in-store using their iPhone, and this innovative capability delivers even more convenience, control, and transparency to even more customers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209410835/en/ The continued expansion follows strong consumer adoption and momentum in Denmark, Spain, Sweden, the U.S., UK and Canada, where Klarna’s flexible payment options have become a popular way to pay with Apple Pay. With today’s launch, consumers across eight major markets can now choose to shop with Klarna through Apple Pay’s simple and secure experience, and consumers have more choice and flexibility in how they can pay. “We’ve seen incredible exciteme
DNP Achieves 10nm Line Pattern Resolution on Nanoimprint Template for Cutting-Edge Semiconductors9.12.2025 12:12:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced the development of a nanoimprint lithography (NIL) template featuring a circuit line width of 10 nanometers (nm: 10-9 meter). The new template enables patterning for logic semiconductors equivalent to the 1.4nm generation and meets the miniaturization needs of cutting-edge logic semiconductors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208175160/en/ Template for nanoimprint Background and Aims In line with the shift to more sophisticated devices seen in recent years, demands have emerged for even greater miniaturization in cutting-edge semiconductors, leading to advances in Extreme Ultra-Violet (EUV) lithography-based production. EUV lithography, however, requires substantial capital investment, energy consumption, and operating costs in building production lines and the exposure process. Since 2003, DNP has been developing NIL templates and has successf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom